Approval · Notice of Compliance 7877 · 2006
SYNAGIS: Notice of Compliance 7877
Issued April 11, 2006
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 7877
- Date
- April 11, 2006
- Company
- Abbott Laboratories Co.Saint-Laurent, Quebec, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Revision to product monograph supporting the use of more than five doses of palivizumab within a single respiratory syncytial virus season
- Therapeutic class
- Passive immunizing agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SYNAGIS | Not yet assigned | — |
Medicinal ingredients
- PALIVIZUMAB 50 MG per VIAL
- PALIVIZUMAB 100 MG per VIAL